+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form



Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form



British Journal of Clinical Pharmacology 19(Suppl. 2): 185s-190s



Plasma oxprenolol concentrations were measured in six young healthy female volunteers after single oral dosing with a 16/260 oxprenolol Oros system on three separate occasions. Reproducibility was assessed by comparing individual plasma profiles, areas under the curve, peak concentrations and times to peak. Plasma concentration-time profiles were consistent with an extended duration of drug release from the Oros system. Individual and mean profiles on the three occasions were similar, and no significant differences in mean plasma levels, or derived pharmacokinetic parameters, were detected. The mean amount of drug in eight systems recovered from faeces corresponded to 11% of the dose. Individual amounts were related to the total transit time of the system through the body. The 16/260 Oros system functioned reproducibly within the gastrointestinal tract, and in vivo absorption mirrored in vitro drug release.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 041242235

Download citation: RISBibTeXText

PMID: 4005121

DOI: 10.1111/j.1365-2125.1985.tb02760.x


Related references

Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. British Journal of Clinical Pharmacology 19(Suppl. 2): 191s-195s, 1985

Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers. British Journal of Clinical Pharmacology 19(Suppl. 2): 197s-201s, 1985

Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers. British Journal of Clinical Pharmacology 19(Suppl. 2): 171s-175s, 1985

A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behavior of polymer matrix and oros dosage forms of oxprenolol in healthy volunteers. British Journal of Clinical Pharmacology 19(SUPPL 2): 177S-184S, 1985

Pre dosing plasma concentrations and beta adrenoceptor blocking effects during repeated once daily dosing with 160 milligram sustained release propranolol inderal la and 16 260 oxprenolol oros to healthy volunteers. British Journal of Clinical Pharmacology 19(SUPPL 2): 197S-202S, 1985

Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. British Journal of Clinical Pharmacology 26(4): 435-443, 1988

Spectrophotometric determination of hydralazine hydrochloride oxprenolol hydrochloride and chlorthalidone in combination and for oxprenolol hydrochloride as single component dosage form. Drug Development & Industrial Pharmacy 16(9): 1539-1554, 1990

Spectrophdtometric Determination of Hydralazine Hydrochloride, Oxprenolol Hydrochloride & Chlorthalidone in Combination and for Oxprenolol Hydrochloride as Single Component Dosage Form. Drug Development and Industrial Pharmacy 16(9): 1539-1554, 1990

Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation. British Journal of Clinical Pharmacology 12(6): 869-871, 1981

Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. British Journal of Clinical Pharmacology 19(Suppl. 2): 163s-169s, 1985

Simultaneous determination of oxprenolol and 2H6-labelled oxprenolol in human plasma by gas chromatography/mass spectrometry. Biomedical Mass Spectrometry 12(6): 269-273, 1985

Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man. European Journal of Clinical Pharmacology 8(1): 3-9, 1975

Comparison of the activity and plasma levels of oxprenolol slow release oxprenolol long acting propranolol and sotalol. European Journal of Clinical Pharmacology 17(6): 419-424, 1980

Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension. European Journal of Clinical Pharmacology 34(6): 605-611, 1988

Hemodynamic effects and variations in plasma renin activity after single oral administration of oxprenolol. Cardiology 59(1): 41-48, 1974